Dr. Jenny Shan (MD, PhD) brings decades of R&D experience from industry leaders like Regeneron, Moderna, J&J, EQRx, Apogee, and Curie.Bio.

Her expertise spans diverse modalitiesвҖ”antibodies, small molecules, ADCs, CAR-T, mRNA, siRNA, peptides, oligonucleotides, AAV, and gene editingвҖ”across oncology, immunology, cardiovascular, neuroscience, and ophthalmology.

As a strategic pipeline architect, Dr. Shan has advanced multiple programs from discovery to clinical development. She supported the IND and regulatory approvals for numerous biologics, contributing to blockbuster drugs such as Eylea, Dupixent, Carvykti, and Rybrevant.

Dr. Qiming Wang earned his Ph.D. in Mammalian Genetics from Tufts University through a joint program with The Jackson Laboratory (JAX), where his research integrated human GWAS with murine transcriptomics to uncover genetic pathways in autoimmune disease.

He is currently Director of Product Strategy and Strategic Partnerships at Cyagen, leading the global expansion of Humanized Genomic Ortholog (HUGO) models and building strategic alliances to accelerate the translation of preclinical research into breakthrough therapies.

Joseph Wekselblatt is an experienced scientist who has studied visual capabilities in various species for over a decade. He holds a Bachelor's degree in Cognitive Science from Brown University and a PhD in Neurobiology from the University of Oregon. After completing his PhD, he worked as a Postdoctoral Researcher at Caltech until 2023, when he joined Cyagen as a Senior Scientific Business Development Manager.